资讯

The Lancet

Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment ...

aThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China bDepartment of ...